Oorja Bio secured a $30M Series A financing led by founding investor Westlake Biopartners to advance its idiopathic pulmonary fibrosis (IPF) and other fibrotic and cardiopulmonary drug pipeline through in-licensing. The company named the round as support for building programs aimed at underserved targets in fibrotic disease biology. The financing also highlights continued investor appetite for specialty respiratory and fibrosis platforms, where clear differentiation and translational relevance can drive valuation. Oorja is positioned to add programs while pushing toward mid-stage execution. For the broader market, the round reflects a focused approach to capital deployment—prioritizing pipeline expansion and development readiness over platform-only spending.